secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tectonic Therapeutic, Inc. (TECX)
CIK:        0001681087
Form:       8-K
Filed at:   2025-05-08T23:59:59+00:00
Accession:  0000950170-25-066932
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tectonic Q1 net loss $15.9M; cash $306M; TX45 Phase 1b shows PCWP reduction 17.9%
--------------------------------------------------------------------------------

- Net loss of $15.9M for Q1 2025 vs $15.2M in Q1 2024; R&D expenses $13.0M, G&A $5.3M.
- Cash and equivalents $306.2M as of Mar 31, 2025, providing runway into Q4 2028; $185M PIPE closed Feb 2025.
- TX45 Phase 1b Part A: 17.9% reduction in PCWP in PH-HFpEF; >30% PVR reduction in CpcPH subgroup.
- Full Phase 1b Part A data to be presented May 17, 2025 at ESC Heart Failure Congress.
- Part B of TX45 Phase 1b (PH-HFrEF) enrolling; topline expected 2H 2025; APEX Phase 2 data expected 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1681087/000095017025066932/0000950170-25-066932-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1681087/000095017025066932/tecx-20250508.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-066932

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer